CPT® Code 90660

1. Indications

The trivalent live influenza virus vaccine (LAIV3) is indicated for the prevention of influenza in individuals who meet specific criteria. The following conditions and circumstances warrant the administration of this vaccine:

• Prevention of Influenza The vaccine is primarily used to protect against influenza virus infections during the flu season, particularly in populations at risk of complications from the disease.
• Age Appropriateness The vaccine is indicated for use in healthy individuals aged 2 through 49 years, as this age group is generally more responsive to the live attenuated vaccine.
• Public Health Recommendations The vaccine is recommended in accordance with public health guidelines to reduce the incidence of influenza and its associated complications in the community.

2. Procedure

The administration of the trivalent live influenza virus vaccine (LAIV3) involves several key procedural steps to ensure effective vaccination:

• Step 1: Patient Assessment Prior to administration, a thorough assessment of the patient’s medical history is conducted to determine eligibility for the vaccine. This includes evaluating any contraindications, such as allergies to vaccine components or a history of severe reactions to previous influenza vaccines.
• Step 2: Preparation of the Vaccine The LAIV3 is prepared according to the manufacturer's instructions. This includes ensuring that the vaccine is stored at the appropriate temperature and is not expired. The vaccine is typically provided in a pre-filled nasal spray device, ready for administration.
• Step 3: Administration of the Vaccine The vaccine is administered intranasally. The patient is instructed to tilt their head slightly back, and the healthcare provider delivers the vaccine into one nostril while ensuring that the patient does not sniff or blow their nose immediately after administration to allow for optimal absorption.
• Step 4: Post-Administration Observation After administration, the patient is monitored for a brief period to observe for any immediate adverse reactions. This is particularly important for individuals with a history of allergies or previous vaccine reactions.

3. Post-Procedure

Following the administration of the trivalent live influenza virus vaccine (LAIV3), patients are advised on post-procedure care and expected outcomes. It is common for individuals to experience mild side effects, such as nasal congestion, runny nose, or mild headache, which typically resolve within a few days. Patients should be informed that the vaccine may take up to two weeks to provide full protection against influenza. Additionally, they should be advised to report any unusual or severe reactions to their healthcare provider. It is also recommended that patients continue to practice good hygiene and follow public health guidelines to further reduce the risk of influenza transmission.